Licensed cultivation
We are developing our cultivation project within the scope of our existing license and the related permit processes. We are planning our operational preparations together with our production responsibilities.
Building quality in medical cannabis from the roots up.
Licensed for medical cannabis cultivation in Türkiye, Novalis is putting Kings Pharmaceutical’s production vision into practice. We are developing a production structure focused on controlled cultivation.
A strong foundation for production in Türkiye
Novalis Pharma is a company licensed for medical cannabis cultivation in Türkiye, with 100 percent of its shares held by Kings Pharmaceutical. Its role is to develop the group’s medical cannabis production activities.
We are building our cultivation infrastructure starting from the quality requirements of the target raw material. The plant’s production history, controlled conditions and documented processes are the foundation of the model we are developing. Our aim is to create a lasting production structure that brings Türkiye’s production potential into the pharmaceutical value chain.
Our purpose
To develop a controlled and traceable production structure for licensed medical cannabis cultivation in Türkiye — bringing the quality requirements of the target raw material to the very start of the cultivation plan, so that it lays a sound foundation for the pharmaceutical stages that follow.
Our long-term goal
To become a cultivation company that contributes to the growth of Türkiye’s medical cannabis production capacity and, through technical discipline and a long-term approach to production, takes its place in the international value chain.
The foundations of our production model
Controlled production infrastructure
We assess the production environment, the needs of the plant and the target quality criteria together. We are basing our facility and process design on production conditions that can be monitored.
Traceable production history
We are preparing a structure built on the integrity of information, from production material through to post-harvest batch records. Access to the history of every batch is, for us, an integral part of the production model.
Integration with the pharmaceutical chain
We approach cultivation together with the requirements of the processing stages that follow it. Our focus is on defining raw material specifications and delivery criteria at the outset of production planning.
Quality is designed before production
At the center of the system we are building at Novalis is consistent raw material that is fit for its intended use. We are developing the cultivation plan alongside its technical requirements, the record-keeping structure alongside day-to-day operations, and the production target alongside long-term supply needs. In this way, we aim to build growth on a solid production foundation.
How we are developing our production structure
At Novalis, we do not treat cultivation readiness as a stand-alone investment in a facility. We design the product target, the production conditions and the information flow of the operation together.
Defining the raw material target
We determine the intended use and target quality attributes of the raw material to be produced, and build the requirements of later processing stages into the cultivation plan.
Preparing the production infrastructure
We are developing the facility and operational layout required for controlled cultivation, with the aim of a production environment that can be monitored and processes that can be run repeatably.
Establishing operations and record-keeping
We plan responsibilities, daily processes and production records within a single structure. We treat the preservation of batch history as one of the core elements of the cultivation model.
Planning the transition to production
We assess operational preparations and the related permit conditions together. The timeline for moving into production will be set in line with the completion of these preparations.
We also plan for the step after cultivation
We consider the value of medical cannabis cultivation together with how the raw material it will yield is to be used in later stages. We do not define our production target by quantity alone; raw material identity, production history and delivery criteria are also part of the plan. This approach supports a clearer technical relationship between cultivation and pharmaceutical processing.
Partnerships that contribute to our production vision
Technology and infrastructure providers
Share your solutions for controlled cultivation, monitoring systems and facility operations, and let’s evaluate them together against our project’s technical needs.
Scientific and academic institutions
Send us your study proposals on plant-based raw materials, quality assessment and production science, and let’s define the scope of suitable research collaborations together.
Corporate supply stakeholders
Share your future raw material needs and technical expectations, and let’s discuss partnership opportunities aligned with the project’s preparation phase and production plan.
A Kings Pharmaceutical subsidiary
Novalis Pharma is a medical cannabis company wholly owned by Kings Pharmaceutical. It is part of the production vision the group is developing in Türkiye, beginning with cultivation, and plans its own field of activity together with the group’s pharmaceutical processing and corporate supply goals.
Frequently asked questions
All shares of Novalis Pharma are held by Kings Pharmaceutical. The company is developing the group’s planned licensed medical cannabis cultivation activities in Türkiye.
Let’s shape the future of production together.
Share your technical expertise, your project or your corporate supply needs with us. Let’s talk about partnership opportunities within the production structure Novalis is developing.